RxDoctor Payments Data

Mark Alexander

Internal Medicine · Ventnor City, NJNPI 1316097223

Payments from drug & device makers

$1,430in general payments, 2019–2025

Across 100 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$306
  • AbbVie$305
  • Novo Nordisk$294
  • Sanofi-aventis U.S. LLC$161
  • AstraZeneca$122
  • Lilly USA, LLC$43
  • plus $199 from 7 others

What the payments were for

  • Food & beverage$1,430100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,430 in reported general payments places this provider in the 70th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$401,749
Medicare patients
283
Services billed
7,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$127,782
JardianceEmpagliflozin30$40,649
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr53$39,415
EliquisApixaban25$38,503
Tresiba Flextouch U-100Insulin Degludec40$35,173
JanuviaSitagliptin Phosphate17$27,863
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$27,135
Combivent RespimatIpratropium/Albuterol Sulfate38$26,664
FarxigaDapagliflozin Propanediol28$26,404
Tresiba Flextouch U-200Insulin Degludec16$23,884
JanumetSitagliptin Phos/Metformin Hcl15$19,668
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$13,597
Breo ElliptaFluticasone/Vilanterol14$13,466
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro14$10,597
LinzessLinaclotide13$10,390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$294$127,78294 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$306$66,47878 claims
MerckJanuvia, Janumet$38$47,53132 claims
PfizerEliquis$40$38,50325 claims
AstraZenecaFarxiga$122$26,40428 claims
AbbVieLinzess, Synthroid$305$12,31535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Ventnor City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →